Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29457357 | 1.00 | ABHD6 (0.36) | ABHD6PIK3R1PIK3CAMTORMAP4K1 | |
| SCHEMBL25342794 | 1.00 | ABHD6 (0.36) | ABHD6PIK3R1PIK3CAMTORMAP4K1 | |
| SCHEMBL9948731 | 0.78 | PIK3CA (0.33) | PIK3CAMTORMAPT | |
| SCHEMBL25321392 | 0.77 | ABHD6 (0.36) | ABHD6 | |
| SCHEMBL30507167 | 0.77 | ABHD6 (0.36) | ABHD6 | |
| SCHEMBL29527168 | 0.76 | GABRA1 (0.41) | PIK3R1PIK3CAMTORMAPT | |
| SCHEMBL28649665 | 0.76 | GABRA1 (0.41) | PIK3R1PIK3CAMTORMAPT | |
| SCHEMBL31451331 | 0.76 | TSHR (0.34) | PIK3CAMTORMAPTAAK1KCNH2 | |
| SCHEMBL24529352 | 0.76 | CNR2 (0.31) | MAP4K1 | |
| SCHEMBL25344562 | 0.76 | APLNR (0.34) | MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976057-B2 | MrgX2 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-05-07 | — | — | US | disclosed |
| US-20220112174-A1 | MRGX2 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11976057-B2 | MrgX2 antagonists | MRGPRX2, MRGPRX1, MRGPRX4 | ABHD6 4324/4885PIK3R1 3410/4885PIK3CA 4494/4885 |
| US-20220112174-A1 | MRGX2 ANTAGONISTS | MRGPRX2, MRGPRX1, MRGPRX4 | ABHD6 4324/4885PIK3R1 3410/4885PIK3CA 4494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.